Immatics (NASDAQ:IMTX - Get Free Report) posted its earnings results on Thursday. The company reported $0.48 EPS for the quarter, topping analysts' consensus estimates of ($0.03) by $0.51, Zacks reports. Immatics had a negative return on equity of 15.90% and a negative net margin of 47.94%. The company had revenue of $15.67 million for the quarter, compared to the consensus estimate of $16.16 million.
Immatics Trading Down 11.3 %
Shares of NASDAQ IMTX traded down $0.51 during trading on Tuesday, reaching $4.00. The company had a trading volume of 2,067,999 shares, compared to its average volume of 628,914. The stock has a market capitalization of $477.42 million, a PE ratio of -6.06 and a beta of 0.83. Immatics has a twelve month low of $3.91 and a twelve month high of $13.77. The stock has a 50-day moving average price of $4.94 and a two-hundred day moving average price of $7.37.
Institutional Trading of Immatics
A hedge fund recently raised its stake in Immatics stock. Bank of America Corp DE lifted its position in shares of Immatics (NASDAQ:IMTX - Free Report) by 166.0% in the fourth quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission (SEC). The institutional investor owned 3,575 shares of the company's stock after buying an additional 2,231 shares during the quarter. Bank of America Corp DE's holdings in Immatics were worth $25,000 at the end of the most recent quarter. 64.41% of the stock is owned by hedge funds and other institutional investors.
Wall Street Analyst Weigh In
Separately, Cantor Fitzgerald reiterated an "overweight" rating on shares of Immatics in a research report on Tuesday. Four research analysts have rated the stock with a buy rating and one has given a strong buy rating to the company's stock. According to MarketBeat, Immatics currently has a consensus rating of "Buy" and a consensus price target of $16.67.
Check Out Our Latest Stock Analysis on Immatics
Immatics Company Profile
(
Get Free Report)
Immatics N.V., a clinical-stage biopharmaceutical company, focuses on the research and development of potential T cell redirecting immunotherapies for the treatment of cancer in the United States. The company is developing targeted immunotherapies with a focus on treating solid tumors through two distinct treatment modalities, such as TCR-engineered autologous or allogeneic adoptive cell therapies (ACT) and antibody-like TCR Bispecifics.
Featured Articles
Before you consider Immatics, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Immatics wasn't on the list.
While Immatics currently has a Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Nuclear energy stocks are roaring. It's the hottest energy sector of the year. Cameco Corp, Paladin Energy, and BWX Technologies were all up more than 40% in 2024. The biggest market moves could still be ahead of us, and there are seven nuclear energy stocks that could rise much higher in the next several months. To unlock these tickers, enter your email address below.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
